|
|
Article: ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available.
- Article from:
- PR Newswire
- Article date:
- December 12, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Provides Rapid Control of Agitation -
PRINCETON, N.J., and TOKYO, Dec. 12 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY(R) (aripiprazole) Injection, an injectable form of ABILIFY, for intramuscular use. ABILIFY Injection provides rapid control of agitation in adults with schizophrenia or bipolar mania at primary endpoint (2 hours). The U.S. Food and Drug Administration (FDA) approved ABILIFY Injection on September 20, 2006.
The urgent nature of acute agitation requires immediate assessment and intervention. ABILIFY Injection provides healthcare professionals with the ...